Abstract
Rucaparib-containing fluorescent probes (1-3) inhibit PARP1 in cell models. One of these (1) was tested in a murine model and shown to permeate into implanted intracranial glioblastoma tumors and persist there for at least 24 h.
Original language | English (US) |
---|---|
Pages (from-to) | 911-915 |
Number of pages | 5 |
Journal | ACS Medicinal Chemistry Letters |
Volume | 13 |
Issue number | 6 |
DOIs | |
State | Published - Jun 9 2022 |
Keywords
- MHI-148
- PARP inhibitor
- cyanine
- glioblastoma
- rucaparib
ASJC Scopus subject areas
- Biochemistry
- Drug Discovery
- Organic Chemistry